Francis M. Sirotnak, PhD, a molecular pharmacologist at Memorial Sloan-Kettering Cancer Center who played a major role in developing anticancer agents, died June 21, 2026, at the age of 94.
Sirotnak obtained a bachelor’s degree in science from the University of Scranton in 1950 and a doctoral degree from the University of Maryland in 1954.
He joined what is now Memorial Sloan-Kettering Cancer Center when it was a division of Cornell University and became an assistant professor of microbiology, rising to chairman of Pharmacology and Molecular Therapeutics at the Sloan-Kettering Institute.
Sirotnak’s laboratory was credited by MSKCC with the development of pralatrexate (Folotyn), which in 2009 became the first drug approved by the FDA for patients with relapsed or refractory peripheral T-cell lymphoma.
A member of the AACR since 1968, Sirotnak served as an Associate Editor of Cancer Research from 1980-1987 and from 1989-2000. He retired from MSKCC as an emeritus member after a career of more than 40 years.
Leave your remembrance of Francis M. Sirotnak, below (limit to 1,000 characters).
Be the first to add a Remembrance.